Marktanalyse - Alzheimer's Disease - Pipeline Review, H1 2017

Global Markets Direct
03.2017
1181 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Alzheimer's Disease - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Pipeline Review, H1 2017, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 23, 40, 62, 1, 251, 90 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 109 and 46 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 12

Alzheimer's Disease - Overview 13

Alzheimer's Disease - Therapeutics Development 14

Alzheimer's Disease - Therapeutics Assessment 78

Alzheimer's Disease - Companies Involved in Therapeutics Development 102

Alzheimer's Disease - Drug Profiles 218

Alzheimer's Disease - Dormant Projects 1072

Alzheimer's Disease - Discontinued Products 1102

Alzheimer's Disease - Product Development Milestones 1108

Appendix 1118





List of Tables

Number of Products under Development for Alzheimer's Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Products under Development by Companies, H1 2017 (Contd..17), H1 2017

Products under Development by Companies, H1 2017 (Contd..18), H1 2017

Products under Development by Companies, H1 2017 (Contd..19), H1 2017

Products under Development by Companies, H1 2017 (Contd..20), H1 2017

Products under Development by Companies, H1 2017 (Contd..21), H1 2017

Products under Development by Companies, H1 2017 (Contd..22), H1 2017

Products under Development by Companies, H1 2017 (Contd..23), H1 2017

Products under Development by Companies, H1 2017 (Contd..24), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..5), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..6), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Alzheimer's Disease - Pipeline by AB Science SA, H1 2017

Alzheimer's Disease - Pipeline by AbbVie Inc, H1 2017

Alzheimer's Disease - Pipeline by AC Immune SA, H1 2017

Alzheimer's Disease - Pipeline by Acadia Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by Accera Inc, H1 2017

Alzheimer's Disease - Pipeline by Acelot Inc, H1 2017

Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, H1 2017

Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H1 2017

Alzheimer's Disease - Pipeline by Affibody AB, H1 2017

Alzheimer's Disease - Pipeline by AFFiRiS AG, H1 2017

Alzheimer's Disease - Pipeline by Alector LLC, H1 2017

Alzheimer's Disease - Pipeline by Allergan Plc, H1 2017

Alzheimer's Disease - Pipeline by Allinky Biopharma, H1 2017

Alzheimer's Disease - Pipeline by ALSP Inc, H1 2017

Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, H1 2017

Alzheimer's Disease - Pipeline by Alzinova AB, H1 2017

Alzheimer's Disease - Pipeline by AlzProtect SAS, H1 2017

Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017

Alzheimer's Disease - Pipeline by Amgen Inc, H1 2017

Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp, H1 2017

Alzheimer's Disease - Pipeline by Annexon Inc, H1 2017

Alzheimer's Disease - Pipeline by Aphios Corp, H1 2017

Alzheimer's Disease - Pipeline by Apodemus AB, H1 2017

Alzheimer's Disease - Pipeline by Applied Research using OMIC Sciences SL, H1 2017

Alzheimer's Disease - Pipeline by Aptevo Therapeutics Inc, H1 2017

Alzheimer's Disease - Pipeline by Araclon Biotech SL, H1 2017

Alzheimer's Disease - Pipeline by Archer Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by ArmaGen Inc, H1 2017

Alzheimer's Disease - Pipeline by Artery Therapeutics Inc, H1 2017

Alzheimer's Disease - Pipeline by Asceneuron SA, H1 2017

Alzheimer's Disease - Pipeline by AskAt Inc, H1 2017

Alzheimer's Disease - Pipeline by Astellas Pharma Inc, H1 2017

Alzheimer's Disease - Pipeline by AstraZeneca Plc, H1 2017

Alzheimer's Disease - Pipeline by Asubio Pharma Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by Axon Neuroscience SE, H1 2017

Alzheimer's Disease - Pipeline by Axovant Sciences Ltd., H1 2017

Alzheimer's Disease - Pipeline by Axxam SpA, H1 2017

Alzheimer's Disease - Pipeline by Beactica AB, H1 2017

Alzheimer's Disease - Pipeline by Berg LLC, H1 2017

Alzheimer's Disease - Pipeline by BioArtic AB, H1 2017

Alzheimer's Disease - Pipeline by Bioasis Technologies Inc, H1 2017

Alzheimer's Disease - Pipeline by Biogen Inc, H1 2017

Alzheimer's Disease - Pipeline by BioHealthonomics Inc, H1 2017

Alzheimer's Disease - Pipeline by Biomar Microbial Technologies, H1 2017

Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H1 2017

Alzheimer's Disease - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Company, H1 2017

Alzheimer's Disease - Pipeline by Bsim2, H1 2017

Alzheimer's Disease - Pipeline by Cantabio Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by Cardax Inc, H1 2017

Alzheimer's Disease - Pipeline by Carna Biosciences Inc, H1 2017

Alzheimer's Disease - Pipeline by Celon Pharma SA, H1 2017

Alzheimer's Disease - Pipeline by CHA Bio & Diostech Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by Clera Inc, H1 2017

Alzheimer's Disease - Pipeline by Cognition Therapeutics Inc, H1 2017

Alzheimer's Disease - Pipeline by Cognosci Inc, H1 2017

Alzheimer's Disease - Pipeline by CohBar Inc, H1 2017

Alzheimer's Disease - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017

Alzheimer's Disease - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by Corium International Inc, H1 2017

Alzheimer's Disease - Pipeline by Coronis NeuroSciences Ltd, H1 2017

Alzheimer's Disease - Pipeline by Cortice Biosciences Inc, H1 2017

Alzheimer's Disease - Pipeline by Critical Outcome Technologies Inc, H1 2017

Alzheimer's Disease - Pipeline by Crossbeta Biosciences BV, H1 2017

Alzheimer's Disease - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Alzheimer's Disease - Pipeline by Daval International Ltd, H1 2017

Alzheimer's Disease - Pipeline by Denali Therapeutics Inc, H1 2017

Alzheimer's Disease - Pipeline by DermaXon LLC, H1 2017

Alzheimer's Disease - Pipeline by Domain Therapeutics SA, H1 2017

Alzheimer's Disease - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by Eisai Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by Eli Lilly and Company, H1 2017

Alzheimer's Disease - Pipeline by EncephRx Inc, H1 2017

Alzheimer's Disease - Pipeline by Endece LLC, H1 2017

Alzheimer's Disease - Pipeline by ENKAM Pharmaceuticals A/S, H1 2017

Alzheimer's Disease - Pipeline by Ensemble Therapeutics Corp, H1 2017

Alzheimer's Disease - Pipeline by Ensol Biosciences Inc, H1 2017

Alzheimer's Disease - Pipeline by Epigen Biosciences Inc, H1 2017

Alzheimer's Disease - Pipeline by Evotec AG, H1 2017

Alzheimer's Disease - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Alzheimer's Disease - Pipeline by Genentech Inc, H1 2017

Alzheimer's Disease - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017

Alzheimer's Disease - Pipeline by Genzyme Corp, H1 2017

Alzheimer's Disease - Pipeline by GlaxoSmithKline Plc, H1 2017

Alzheimer's Disease - Pipeline by GliaCure Inc, H1 2017

Alzheimer's Disease - Pipeline by Glialogix Inc, H1 2017

Alzheimer's Disease - Pipeline by Golden Biotechnology Corp, H1 2017

Alzheimer's Disease - Pipeline by Grifols SA, H1 2017

Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H1 2017

Alzheimer's Disease - Pipeline by Heptares Therapeutics Ltd, H1 2017

Alzheimer's Disease - Pipeline by HitGen LTD, H1 2017

Alzheimer's Disease - Pipeline by HSRx Group, H1 2017

Alzheimer's Disease - Pipeline by ICB International Inc, H1 2017

Alzheimer's Disease - Pipeline by Ichor Medical Systems Inc, H1 2017

Alzheimer's Disease - Pipeline by Icure Pharmaceutical Inc, H1 2017

Alzheimer's Disease - Pipeline by Immungenetics AG, H1 2017

Alzheimer's Disease - Pipeline by Impel NeuroPharma Inc, H1 2017

Alzheimer's Disease - Pipeline by ImStar Therapeutics Inc, H1 2017

Alzheimer's Disease - Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by IntelGenx Corp, H1 2017

Alzheimer's Disease - Pipeline by Intellect Neurosciences Inc, H1 2017

Alzheimer's Disease - Pipeline by Intra-Cellular Therapies Inc, H1 2017

Alzheimer's Disease - Pipeline by INVENT Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by Io Therapeutics Inc, H1 2017

Alzheimer's Disease - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by Johnson & Johnson, H1 2017

Alzheimer's Disease - Pipeline by K-Stemcell Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by Kadmon Corp LLC, H1 2017

Alzheimer's Disease - Pipeline by Kalgene Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by Kareus Therapeutics SA, H1 2017

Alzheimer's Disease - Pipeline by Karuna Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by KineMed Inc, H1 2017

Alzheimer's Disease - Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by Lead Discovery Center GmbH, H1 2017

Alzheimer's Disease - Pipeline by Les Laboratoires Servier SAS, H1 2017

Alzheimer's Disease - Pipeline by Lipopharma Therapeutics SL, H1 2017

Alzheimer's Disease - Pipeline by Living Cell Technologies Ltd, H1 2017

Alzheimer's Disease - Pipeline by Lupin Ltd, H1 2017

Alzheimer's Disease - Pipeline by M3 Biotechnology Inc, H1 2017

Alzheimer's Disease - Pipeline by ManRos Therapeutics, H1 2017

Alzheimer's Disease - Pipeline by MedDay SA, H1 2017

Alzheimer's Disease - Pipeline by Medestea Research & Production SpA, H1 2017

Alzheimer's Disease - Pipeline by MedImmune LLC, H1 2017

Alzheimer's Disease - Pipeline by Medisyn Technologies Inc, H1 2017

Alzheimer's Disease - Pipeline by MEDRx Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by MEI Pharma Inc, H1 2017

Alzheimer's Disease - Pipeline by MeiraGTx Ltd, H1 2017

Alzheimer's Disease - Pipeline by Merck & Co Inc, H1 2017

Alzheimer's Disease - Pipeline by Metabolic Solutions Development Company LLC, H1 2017

Alzheimer's Disease - Pipeline by Microlin Bio Inc, H1 2017

Alzheimer's Disease - Pipeline by Mithridion Inc, H1 2017

Alzheimer's Disease - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Alzheimer's Disease - Pipeline by ModGene Pharma LLC, H1 2017

Alzheimer's Disease - Pipeline by NAL Pharmaceuticals Ltd, H1 2017

Alzheimer's Disease - Pipeline by Nanomerics Ltd, H1 2017

Alzheimer's Disease - Pipeline by Nanotherapeutics Inc, H1 2017

Alzheimer's Disease - Pipeline by Neuralstem Inc, H1 2017

Alzheimer's Disease - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017

Alzheimer's Disease - Pipeline by Neuro-Sys SAS, H1 2017

Alzheimer's Disease - Pipeline by NeuroGenetic Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by NeuroNascent Inc, H1 2017

Alzheimer's Disease - Pipeline by NeurOp Inc, H1 2017

Alzheimer's Disease - Pipeline by Neuropore Therapies Inc, H1 2017

Alzheimer's Disease - Pipeline by Neurotez Inc, H1 2017

Alzheimer's Disease - Pipeline by New World Laboratories Inc, H1 2017

Alzheimer's Disease - Pipeline by nLife Therapeutics SL, H1 2017

Alzheimer's Disease - Pipeline by NLS Pharma Group, H1 2017

Alzheimer's Disease - Pipeline by Novartis AG, H1 2017

Alzheimer's Disease - Pipeline by NsGene A/S, H1 2017

Alzheimer's Disease - Pipeline by Oligomerix inc, H1 2017

Alzheimer's Disease - Pipeline by Orphit SAS, H1 2017

Alzheimer's Disease - Pipeline by Oryzon Genomics SA, H1 2017

Alzheimer's Disease - Pipeline by P2D Bioscience, H1 2017

Alzheimer's Disease - Pipeline by Pain Therapeutics Inc, H1 2017

Alzheimer's Disease - Pipeline by Palumed SA, H1 2017

Alzheimer's Disease - Pipeline by Panacea Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by Peptron Inc, H1 2017

Alzheimer's Disease - Pipeline by Pfizer Inc, H1 2017

Alzheimer's Disease - Pipeline by PharmaKure Ltd, H1 2017

Alzheimer's Disease - Pipeline by PharmatrophiX Inc, H1 2017

Alzheimer's Disease - Pipeline by Pharmaxis Ltd, H1 2017

Alzheimer's Disease - Pipeline by Pharnext SA, H1 2017

Alzheimer's Disease - Pipeline by Prevacus Inc, H1 2017

Alzheimer's Disease - Pipeline by Probiodrug AG, H1 2017

Alzheimer's Disease - Pipeline by Proclara Biosciences Inc, H1 2017

Alzheimer's Disease - Pipeline by Progenra Inc, H1 2017

Alzheimer's Disease - Pipeline by ProMIS Neurosciences Inc, H1 2017

Alzheimer's Disease - Pipeline by ProQR Therapeutics NV, H1 2017

Alzheimer's Disease - Pipeline by Proteome Sciences Plc, H1 2017

Alzheimer's Disease - Pipeline by Proteostasis Therapeutics Inc, H1 2017

Alzheimer's Disease - Pipeline by QR Pharma Inc, H1 2017

Alzheimer's Disease - Pipeline by Quimatryx SL, H1 2017

Alzheimer's Disease - Pipeline by Radius Health Inc, H1 2017

Alzheimer's Disease - Pipeline by Regenera Pharma Ltd, H1 2017

Alzheimer's Disease - Pipeline by reMYND NV, H1 2017

Alzheimer's Disease - Pipeline by Resverlogix Corp, H1 2017

Alzheimer's Disease - Pipeline by Retrotope Inc, H1 2017

Alzheimer's Disease - Pipeline by ReXceptor Inc, H1 2017

Alzheimer's Disease - Pipeline by Rodos BioTarget GmbH, H1 2017

Alzheimer's Disease - Pipeline by Sage Therapeutics Inc, H1 2017

Alzheimer's Disease - Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by Samumed LLC, H1 2017

Alzheimer's Disease - Pipeline by SanBio Inc, H1 2017

Alzheimer's Disease - Pipeline by Saneron CCEL Therapeutics Inc, H1 2017

Alzheimer's Disease - Pipeline by Sanofi, H1 2017

Alzheimer's Disease - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by Selvita SA, H1 2017

Alzheimer's Disease - Pipeline by SeneXta Therapeutics SA, H1 2017

Alzheimer's Disease - Pipeline by Serometrix LLC, H1 2017

Alzheimer's Disease - Pipeline by Signum Biosciences Inc, H1 2017

Alzheimer's Disease - Pipeline by Simcere Pharmaceutical Group, H1 2017

Alzheimer's Disease - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by SOM Biotech SL, H1 2017

Alzheimer's Disease - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by Spherium Biomed SL, H1 2017

Alzheimer's Disease - Pipeline by Stemedica Cell Technologies Inc, H1 2017

Alzheimer's Disease - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by Summit Therapeutics Plc, H1 2017

Alzheimer's Disease - Pipeline by Suven Life Sciences Ltd, H1 2017

Alzheimer's Disease - Pipeline by T3D Therapeutics Inc, H1 2017

Alzheimer's Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Alzheimer's Disease - Pipeline by TauRx Therapeutics Ltd, H1 2017

Alzheimer's Disease - Pipeline by TechnoPhage SA, H1 2017

Alzheimer's Disease - Pipeline by Teijin Pharma Ltd, H1 2017

Alzheimer's Disease - Pipeline by Teikoku Pharma USA Inc, H1 2017

Alzheimer's Disease - Pipeline by Telocyte LLC, H1 2017

Alzheimer's Disease - Pipeline by Tetra Discovery Partners LLC, H1 2017

Alzheimer's Disease - Pipeline by Thera Neuropharma Inc, H1 2017

Alzheimer's Disease - Pipeline by Theranexus SAS, H1 2017

Alzheimer's Disease - Pipeline by Therapix Biosciences Ltd, H1 2017

Alzheimer's Disease - Pipeline by Toyama Chemical Co Ltd, H1 2017

Alzheimer's Disease - Pipeline by Treventis Corp, H1 2017

Alzheimer's Disease - Pipeline by UCB SA, H1 2017

Alzheimer's Disease - Pipeline by Varinel Inc, H1 2017

Alzheimer's Disease - Pipeline by Virobay Inc, H1 2017

Alzheimer's Disease - Pipeline by Vitae Pharmaceuticals Inc, H1 2017

Alzheimer's Disease - Pipeline by VLP Therapeutics LLC, H1 2017

Alzheimer's Disease - Pipeline by Voyager Therapeutics Inc, H1 2017

Alzheimer's Disease - Pipeline by vTv Therapeutics Inc, H1 2017

Alzheimer's Disease - Pipeline by Vybion Inc, H1 2017

Alzheimer's Disease - Pipeline by Wellstat Therapeutics Corp, H1 2017

Alzheimer's Disease - Pipeline by Xigen SA, H1 2017

Alzheimer's Disease - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..1), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..2), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..3), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..4), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..5), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..6), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..7), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..8), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..9), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..10), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..11), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..12), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..13), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..14), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..15), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..16), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..17), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..18), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..19), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..20), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..21), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..22), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..23), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..24), H1 2017

Alzheimer's Disease - Dormant Projects, H1 2017 (Contd..25), H1 2017

Alzheimer's Disease - Discontinued Products, H1 2017

Alzheimer's Disease - Discontinued Products, H1 2017 (Contd..1), H1 2017

Alzheimer's Disease - Discontinued Products, H1 2017 (Contd..2), H1 2017

Alzheimer's Disease - Discontinued Products, H1 2017 (Contd..3), H1 2017

Alzheimer's Disease - Discontinued Products, H1 2017 (Contd..4), H1 2017

Alzheimer's Disease - Discontinued Products, H1 2017 (Contd..5), H1 2017





List of Figures

Number of Products under Development for Alzheimer's Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus